08th week of 2010 patent applcation highlights part 56 |
Patent application number | Title | Published |
20100048621 | MEDICAMENT FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The invention relates to a medicament for treating chronic obstructive pulmonary disease comprising as active ingredients a carbostyril derivative of formula (1): wherein A is a lower alkylene group, R is a cycloalkyl group, the bonding between 3- and 4-positions of the carbostyril skeleton is a single bond or a double bond, or a salt thereof; and probucol. | 2010-02-25 |
20100048622 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND - The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder. | 2010-02-25 |
20100048623 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - Compounds of formula (I) are modulators of gamma-secretase, and hence are useful in treatment of Alzheimer's disease. | 2010-02-25 |
20100048624 | USE OF PIPERIDINE DERIVATIVES AS DERMO-DECONTRACTING AGENTS - The present invention relates to a cosmetic process for treating wrinkled skin, in particular the skin of the face and/or of the forehead, through a dermo-decontracting effect, comprising the topical application to said skin of a composition comprising, in a physiologically acceptable medium, at least one piperidine derivative chosen from the compounds of formula (I): | 2010-02-25 |
20100048625 | PIPERIDINE GPCR AGONISTS - Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes. | 2010-02-25 |
20100048626 | Aryl Substituted Pyridines and the Use Thereof - This invention relates aryl substituted pyridines of Formula I: | 2010-02-25 |
20100048627 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR TREATMENT OF DIABETES - The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus. | 2010-02-25 |
20100048628 | METHOD FOR SUPPRESSING DISCOLORATION OVER TIME OF ADHESIVE PREPARATION CONTAINING DONEPEZIL - [Object] Discoloration, over time, of a donepezil-containing adhesive preparation is suppressed. | 2010-02-25 |
20100048629 | METHODS FOR TREATING NEUROPATHIC PAIN - The present invention relates to methods of treating diabetic neuropathic pain comprising administering piperidine derivatives, such as 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)acetamide, and pharmaceutically acceptable salts thereof. Methods of treating post-herpetic neuralgia, chronic lower back pain, osteoarthritis and acute inflammatory pain are described. | 2010-02-25 |
20100048630 | METHODS FOR TREATING CNS DISORDERS - The present invention relates to methods for treating central nervous system disorders, such as Alzheimer's disease, anxiety and major depressive disorder, by administering piperidine derivatives, e.g., 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)acetamide, and pharmaceutically acceptable salts thereof. | 2010-02-25 |
20100048631 | Piperidine GPCR Agonists - Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes. | 2010-02-25 |
20100048632 | Piperidine GPCR Agonists - Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes. | 2010-02-25 |
20100048633 | Piperidine-4-acrylamides - A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3. | 2010-02-25 |
20100048634 | METHOD FOR TREATING APATHY SYNDROME - The present invention provides a method of treating apathy syndrome in a human subject. The human subject is first evaluated to determine whether one or more behavioral characteristics of apathy are observed. If such characteristics are observed, the subject is treated with a 2-oxopyrrolidine compound, such as nefiracetam, piracetam, aniracetam, pramiracetam, nebracetam, fasoracetam, levetiracetam, or oxiracetam, in an amount effective to produce an improvement in such apathy characteristics. The present invention is useful in treating apathy in a subject suffering from conditions associated with or characterized by frontal-subcortical dysfunction. The present invention is also useful in treating apathy in a subject suffering from a stroke, Alzheimer's disease, Parkinson's disease, traumatic brain injury, depression, schizophrenia, chronic hepatitis C infection, or HIV infection. | 2010-02-25 |
20100048635 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS - The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease. | 2010-02-25 |
20100048636 | Aspartic Protease Inhibitors - The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors. | 2010-02-25 |
20100048637 | CYCLOHEXYLAMINES, PHENYLAMINES AND USES THEREOF - Compounds having the formula I, their methods of synthesis, and pharmaceutically acceptable salts of certain of them are provided in which the variables have the definitions described herein. | 2010-02-25 |
20100048638 | HEPARAN SULFATE INHIBITORS - Provided herein are heparan sulfate inhibitors, including modulators of heparan sulfate glycosylation, heparan sulfate sulfation, and/or heparan sulfate epimerization. | 2010-02-25 |
20100048639 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS - The present invention relates to novel oxadiazole compounds of formula (I) | 2010-02-25 |
20100048640 | HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME - Disclosed is a hydrazine compound represented by the formula (1) below, which has an excellent control activity against a harmful arthropod. (1) (In the formula, R | 2010-02-25 |
20100048641 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases - The present invention relates to the use of A1 and/or dual A1/A2 | 2010-02-25 |
20100048642 | METHODS FOR TREATING COGNITIVE DISORDERS - Disclosed herein are methods of treating a patient suffering a cognitive disorder. | 2010-02-25 |
20100048643 | Novel Polymorph Forms Of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine - Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders. | 2010-02-25 |
20100048645 | Solubilizing of metronidazole - Metronidazole is solubilized in an aqueous phase, by mixing same with niacinamide and at least two glycolic cosolvents; the resulting solutions and pharmaceutical compositions comprised thereof are useful for the treatment of dermatological conditions/afflictions, notably rosacea. | 2010-02-25 |
20100048646 | N'-Cyano-N-Halogenalkylimidamide Derivatives - The present application relates to novel substituted N′-cyano-N-halogenalkylimidamide derivatives, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects. | 2010-02-25 |
20100048647 | NEMATICIDAL AGENT COMPOSITION AND METHOD OF USING THE SAME - The present invention provides a nematocide containing, as an active ingredient, an N-2-(pyridyl)ethylcarboxamide derivative represented by the formula (I): | 2010-02-25 |
20100048648 | Thiophene derivatives as S1P1/EDGE1 receptor agonists - The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. | 2010-02-25 |
20100048649 | COMBINATIONS COMPRISING BICYCLIC S1P LYASE INHIBITORS - Methods and compositions for treating immunological and inflammatory diseases and disorders are disclosed. Particular methods and compositions comprise the administration of an agent that inhibits S1P lyase activity and at least one additional immunosuppressive and/or anti-inflammatory agent. | 2010-02-25 |
20100048650 | TWO PORE CHANNELS AS A THERAPEUTIC TARGET TO PROTECT AGAINST MYOCARDIAL ISCHEMIA AND AS AN ADJUVANT IN CARDIAC SURGERY - The present invention relates to methods and compositions for modulating the activity of two-pore domain K+ channels (“K2P channels”) as a means for inducing preconditioning protection. Such preconditioning can be used to reduce the effect of ischemia associated with ischemic heart disease, myocardial infarcation or cardiac surgery. The invention is based on the discovery that the myoprotective current induced by short periods of ischemia is carried by a non-classical two-pore domain K+ channel. | 2010-02-25 |
20100048651 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed. | 2010-02-25 |
20100048652 | INSECTICIDAL COMPOUNDS - A compound of formula (I): wherein A | 2010-02-25 |
20100048653 | NEUROPROTECTIVE MODULATION OF NMDA RECEPTOR SUBTYPE ACTIVITIES - In various aspects, the invention provides methods and compositions for modulating NMDA receptor subtype activity, to enhance NR2A-containing NMDA receptor activity relative to NR2B-containing NMDA receptor activity, so as to effect a neuroprotective reduction in excitotoxic NMDA receptor activity | 2010-02-25 |
20100048654 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION - The invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of an ARB or its metabolite, especially Valsartan or its metabolite valeryl 4-hydroxy valsartan. Conditions to be treated by inhibition of platelet aggregation include acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion. | 2010-02-25 |
20100048655 | Comb Polymers and Use Thereof for the Production of Active or Effective Ingredient Formulations - The present invention relates to novel comb polymers, to a process for their manufacture and to the use thereof in the stabilization in an aqueous phase of active or effect substances which are insoluble or sparingly soluble in water. The invention furthermore relates to the use of the comb polymers in the manufacture of active substance formulations or active substance preparations of water-insoluble active or effect substances, in particular of active substances for plant protection. | 2010-02-25 |
20100048656 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - Compounds of formula (I) or a salt thereof are provided: | 2010-02-25 |
20100048657 | CONTROL OF MALIGNANT CELLS PROLIFERATION THROUGH THE INHIBITION OF CASEIN KINASE 2 - Methods and related compositions are disclosed for treating an array of myeloproliferative disorders and hematological malignancies. In particular, treatment methods and compositions for treating chronic myelogenous leukemia are disclosed. The methods and compositions utilize certain casein kinases, and specifically CK2α agents. | 2010-02-25 |
20100048658 | FUSED HETEROCYCLIC COMPOUNDS - There is provided a compound of the formula: | 2010-02-25 |
20100048659 | Aqueous compositions containing metronidazole - An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.7%. The solution contains a combination of solubility-enhancing agents, one of which is niacinamide. Methods of manufacture and therapeutic use of the solution are disclosed. | 2010-02-25 |
20100048660 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - There are disclosed compound of Formula (I) or (II) wherein A | 2010-02-25 |
20100048661 | Active Compound Combinations Having Insecticidal and Acaricidal Properties - The novel active compound combinations consisting, firstly, of cyclic ketoenols and, secondly, of beneficial species (natural enemies) have very good insecticidal and/or acaricidal properties. | 2010-02-25 |
20100048662 | Novel Pyrone-Indole Derivatives and Process for Their Preparation - The present invention relates to novel pyrone-indole derivatives, pharmaceutical formulations containing them, and use of the compounds in the manufacture of Medicaments for treating or preventing various diseases. | 2010-02-25 |
20100048663 | Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents - This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3β kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders. | 2010-02-25 |
20100048664 | THERAPEUTIC SUBSTITUTED PYRROLES - Disclosed herein is a compound represented by a formula: | 2010-02-25 |
20100048665 | 3-AMINOPYRROLIDONE DERIVATIVES - 3-aminopyrrolidone compounds and pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases. | 2010-02-25 |
20100048666 | NOVEL PHENYLACETIC ACID DERIVATIVE - A compound represented by the formula (1) or a salt thereof ( | 2010-02-25 |
20100048667 | Thiolactones - This invention provides new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, inhibiting angiogenesis, effecting a TGF-β activity or a neuronal activity, and treating a glutamate abnormality, a compulsive disorder, neuropathy, pain, a prostate disease, cancer, Huntington's disease, diabetes, a retinal disorder or glaucoma. | 2010-02-25 |
20100048668 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH - A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. They can be used alone or in combination with other therapies to treat cancer and other cell proliferative diseases. Representative compounds of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide and N,N-diethyl-N-allyl-3-(2-methyl-9H-thioxanthen-9-ylidene)-propane-1-aminium bromide, were shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. These compounds had even greater effects on tumor volume, body weight, and survival when administered together with the human protein placental alkaline phosphatase. | 2010-02-25 |
20100048669 | THERAPEUTIC COMPOUNDS - Disclosed herein are compounds of the formula | 2010-02-25 |
20100048670 | Stable and Long-Lasting siRNA Expression Vectors and the Applications Thereof - The invention relates to a siRNA expression vector that can inhibit or eliminate the expression of a target gene in a mammalian cell, said vector comprising: a bacterial cassette containing a bacterial origin of replication and a bacterial selection marker M1; a eucaryotic cell selection cassette comprising a marker M2 for selecting eucaryotic cells under the control of an appropriate promoter; a cassette EBV comprising at least one fragment of the antigen EBNA-1, at least one fragment FR, and at least one fragment of the region DYAD; and a siRNA transcription cassette comprising at least one region coding for a siRNA corresponding to the target gene to be inhibited or eliminated, under the control of elements for regulating transcription in mammalian cells, said regulating elements including at least one promoter capable of transcribing a siRNA in mammalian cells, and a transcription terminator. The invention also relates to the applications of one such expression vector. | 2010-02-25 |
20100048671 | INHIBITION OF THE 44 KILODALTON ISOFORM OF PIM-1 KINASE RESTORES APOPTOSIS INDUCED BY CHEMOTHERAPEUTIC DRUGS IN CANCER CELLS - The present invention relates to a newly discovered 44 kD isoform of Pim-1 kinase made in human cells, and to the gene and messenger RNA for the 44 kilodalton isoform. The invention further describes methods and compounds for treating, especially prostate and hematopoietic cancer, by inhibiting expression of the 44 kD isoform of Pim-1 kinase, or its ability to phosphorylate Etk kinase and breast cancer resistance protein (BCRP). | 2010-02-25 |
20100048672 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS - The invention relates to compositions of transfection comprising an oligonucleotide and an amphiphilic cationic molecule of formula (I) wherein, —X is N—R | 2010-02-25 |
20100048673 | OLIGONUCLEOTIDES AFFECTING EXPRESSION OF PHOSPHODIESTERASES - The invention relates to therapeutic antisense oligonucleotides directed against genes encoding phosphodiesterases (PDE) and the use of these antisense oligonucleotides in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial. | 2010-02-25 |
20100048674 | Role of miRNA in T cell leukemia - The ability of miR-181a to support active signaling between Notch and pre-TCR pathways by coordinately dampening negative regulators of these pathways allows the use of miR-181a as a therapeutic target for T-ALL. | 2010-02-25 |
20100048675 | miRNA TRIPLEX FORMATIONS FOR THE DOWNREGULATION OF VIRAL REPLICATION - As discovered herein, using miRNAs having high homology with both HIV- | 2010-02-25 |
20100048676 | Non-androgen dependent roles for androgen receptor in liver cancer - Disclosed are compositions and methods for modulating AR activity, such as non-androgen dependent AR activity. Also disclosed are compositions and methods for diagnosing beast cancer and for inhibiting liver cancer growth. In addition, disclosed are methods for identifying molecules that inhibit AR in non-androgen dependent ways. | 2010-02-25 |
20100048677 | Regulation of Integrin Surface Expression - Disclosed are methods and compositions for preventing and treating conditions associated with platelet aggregation, comprising administering a therapeutically effective amount of a composition that modifies the interaction of DNAJC10 with αIIbβ3 in a megakaryocyte, thereby altering the expression of αIIbβ3 on the surface of the megakaryocyte. | 2010-02-25 |
20100048678 | Nucleic acids and polypeptides that are useful in controlling neuronal regeneration - The present invention relates to methods for promoting regeneration response of peripheral and central nervous systems in mammals in need of such biological effects. The methods comprise altering the activity or steady state level of specific polypeptides that control regeneration of injured or degenerated neuronal cells. Preferably the activity or steady state level of specific polypeptides is altered by introducing nucleic acids to increase or decrease expressing of the polypeptides. These are useful in or suffering from neurodegenerative disorders. | 2010-02-25 |
20100048679 | POLYNUCLEOTIDE THERAPY - This invention provides methods of treating an autoimmune disease in a subject associated with one or more self-protein(s), polypeptide(s), or peptide(s) present in the subject non-physiologically comprising administering to the subject: a self-vector comprising an immunosuppressive vector backbone and a polynucleotide encoding the self-protein(s), polypeptide(s) or peptide(s) associated with the autoimmune disease; and a divalent cation at a concentration greater than physiological levels. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), polypeptide(s) or peptide(s) modulates an immune response to the self-protein(s), polypeptide(s) or peptide(s) expressed from administration of the self-vector This invention further provides a method of treating multiple sclerosis by administering a self-vector comprising a BHT-1 vector backbone, for example, self-vector BHT-3009 encoding human myelin basic protein (MBP). The invention also provides a pharmaceutical composition comprising: a BHT-1 vector backbone and a polynucleotide encoding one or more self-protein(s), polypeptide(s), or peptide(s) associated with an autoimmune disease; and a divalent cation at concentrations greater than physiological levels. This invention further provides a pharmaceutical composition comprising a self-vector comprising a BHT-1 vector backbone, for example, self-vector BHT-3009 encoding human myelin basic protein (MBP), and methods of administering a BHT-1 self-vector, for example BHT-3009, to a subject. | 2010-02-25 |
20100048680 | Alpha-1-Antitrypsin Variants and Uses Thereof - The subject invention is directed to novel polynucleotides and polypeptides comprising SEQ ID NOs: 1 and 2. Also provided arc fragments these polypeptides. The polynucleotides and polypeptides disclosed herein have been isolated from the liver cells (hepatocytes) of end stage liver failure patients and appear to be associated with a poor prognosis for these patients as relates to liver function. The subject application provides therapeutic methods and reagents for treating livers in which the polynucleotide and polypeptide of SEQ ID NO: 1 and 2 are identified as well as diagnostic methods and reagents for identifying individuals at risk of liver failure. Finally, the subject invention also provides a system of the classification, revision or reordering of a classification system of liver transplant patients. | 2010-02-25 |
20100048681 | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Acute Myeloid Leukemia (AML) - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML). The invention also provides methods of identifying anti-AML agents. | 2010-02-25 |
20100048682 | INHIBITING DNA POLYMERASE BETA TO ENHANCE EFFICACY OF ANTICANCER AGENTS - The invention provides anticancer methods. In one embodiment, the inventive method involves the co-administration to cancerous cells of (a) a chemotherapeutic agent, radiation, or a combination of a chemotherapeutic agent and radiation and (b) an inhibitor of DNA polymerase beta. In another embodiment, the invention provides anticancer methods involving the co-administration to cancerous cells of (a) a chemotherapeutic agent, radiation, or a combination of a chemotherapeutic agent and radiation and (b) an siRNA or shRNA in an amount sufficient to attenuate base excision repair within the cell. Another aspect of the invention relates to pharmaceutical compositions comprising an siRNA or shRNA that attenuates base excision repair. | 2010-02-25 |
20100048683 | MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES - The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3. | 2010-02-25 |
20100048684 | EGF RECEPTOR TRANSACTIVATION BY G-PROTEIN-COUPLED RECEPTORS REQUIRES METALLOPROTEINASE CLEAVAGE OF proHB-EGF - The present invention relates to agents and methods for growth-factor receptor activation by modulating the G-protein mediated signal transduction pathway. | 2010-02-25 |
20100048685 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL-CYCLODEXTRIN INCLUSION COMPLEX AND ITS PREPARING PROCESS - A docetaxel inclusion complex having improved water-solubility (up to 15 mg/ml) and stability (stability constant Ka=2056M | 2010-02-25 |
20100048686 | Perfume Composition For Temperature Sense Control, Sense Control Article, Sense Control Method, And Perfume Map - It is an object of the present invention to discover that a perfume can change a person's temperature sense and humidity sense, to identify a perfume component that can change temperature sense, and to provide a perfume composition for controlling temperature sense that contains this perfume component, and to a sense control method or sense control article such as an aromatic or a cosmetic that is beneficial for controlling temperature sense, and to a perfume map for selecting a perfume suited to controlling temperature sense. The perfume composition is characterized in that a perfume component that changes the temperature subjectively sensed by a person (temperature sense) is contained, and that the perfume component that changes the temperature sense is a perfume component identified on the basis of a temperature image obtained from test subject assessment. | 2010-02-25 |
20100048687 | USE OF PHOSPHATASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - Provided are novel a target and drugs in the treatment of neurological disorders related to amyloid beta pathology/amyloidosis. More specifically, the use of phosphatase inhibitors for the treatment of brain impairments mediated by Aβ-oligomers is described. | 2010-02-25 |
20100048688 | DIETARY AND PHARMACEUTICAL COMPOSITIONS CONTAINING CARNOSOL AND/OR ROSMANOL AND THEIR USES - The present invention refers to carnosol and rosmanol for use (as medicament) in the treatment of a disorder connected to reduced neurotransmission, cognitive dysfunction and/or symptoms caused by headache and/or migraine, as well as to dietary and pharmaceutical compositions and their uses. | 2010-02-25 |
20100048689 | PROCESS OF OBTAINMENT OF SOY ISOFLAVONES - The present invention relates to the process for the recovery of conjugated isoflavones of residues and sub-products of food industries based on the use of soy and its derivatives. It also concerns of isoflavones obtained from food composition containing isoflavones and from the fungus genetically modified used in this process, | 2010-02-25 |
20100048690 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS - Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus | 2010-02-25 |
20100048691 | COMPOSITION USEFUL FOR THE PREVENTION OF TYPE 2 DIABETES AND ITS COMPLICATIONS IN PRE-DIABETIC PATIENTS WITH INSULIN RESISTANCE - The present invention relates to the use of acetyl L-carnitine in combination with an anti hypertensive drug, and a statin, for the preparation of a medicament for the prevention or delay of onset of type 2 diabetes and its complications, in pre-diabetic patients with insulin resistance. | 2010-02-25 |
20100048692 | Naphthofuranone Derivatives as Specific Inhibitors of Thymidylate Synthases - Synthetic compounds of 1,2-naphthalein moelcules (I) having specific inhibitory properties of the enzymatic activity of thymidylate synthases of bacterial species, their preparation, their pharmaceutical composition and use in the treatment and prophylaxis of infectious pathologies are disclosed. | 2010-02-25 |
20100048693 | Treatment of COPD - The present invention provides methods for treating chronic obstructive pulmonary disease. In some embodiments of the invention, methods for treating COPD comprise administering PGI | 2010-02-25 |
20100048694 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY - Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. | 2010-02-25 |
20100048695 | ANTI-FATIGUE AGENT - Anti-fatigue agents containing dioxabicyclo[3.3.0]octane derivatives such as sesamin which is an ingredient contained in sesame, as well as pharmaceutical compositions and physiologically functional foods that contain such anti-fatigue agents are disclosed. These compounds can safely be administered to humans and animals alike and hence allow for continued ingestion while proving effective in promoting an improvement of stamina, an increase of body strength, a relief of fatigue, and recovery from fatigue. | 2010-02-25 |
20100048696 | AGRICULTURAL DISEASE CONTROL AGENT - The present invention provides a disinfectant comprising as an active ingredient maleic acid and/or maleic anhydride. | 2010-02-25 |
20100048697 | WATER-SOLUBLE STRONTIUM SALTS FOR USE IN TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS - Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid. | 2010-02-25 |
20100048698 | MACROCYCLIC DITERPENES FOR TREATING CONDITIONS ASSOCIATED WITH PROTEIN KINASE C - The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species. The present invention further contemplates a method for the prophylaxis or treatment of mammalian, animal or avian subjects for inflammatory conditions including chronic or transitory inflammatory conditions or for ameliorating the symptoms of an inflammatory condition by the topical or systemic administration of a macrocyclic diterpene obtainable from a member of the Fuphorbiaceae family or botanical or horticultural relatives thereof or a derivative, chemical analogue or chemically synthetic form of the agent. The chemical agent of the present invention may be in the form of a purified compound, mixture of compounds, a precursor form of one or more of the compounds capable of chemical transformation into a therapeutically active agent or be in the form of a chemical fraction, sub-fraction or preparation or extract of the plant. | 2010-02-25 |
20100048699 | CHEMICAL COMPOUNDS - A compound of formula I | 2010-02-25 |
20100048700 | LIQUID FORMULATION OF PYRETHROIDS - New agrochemical formulations have been found, comprising
| 2010-02-25 |
20100048701 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES - Disclosed is an amide compound represented by the formula (1) below, which has excellent plant disease controlling activity. | 2010-02-25 |
20100048702 | PREVENTION OF NEUTROPHIL RECRUITMENT - Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II. | 2010-02-25 |
20100048703 | Hair care product - A substance having a testosterone 5α-reductase inhibiting action, a hair papilla cell growth promoting action, a fibroblast growth factor-7 production promoting action, a vascular endothelial growth factor production promoting action or a bone morphogenetic protein-2 production promoting action, and a hair care product having this substance blended therein. A hair growth tonic, a testosterone 5α-reductase inhibitor, a hair papilla cell growth promoter, a fibroblast growth factor-7 production promoter, a vascular endothelial growth factor production promoter and a bone morphogenetic protein-2 production promoter each having this substance, such as corosolic acid, as an active ingredient thereof. | 2010-02-25 |
20100048704 | PHARMACEUTICAL AND NUTRACEUTICAL PRODUCTS COMPRISING VITAMIN K2 - A pharmaceutical and nutraceutical product is provided comprising vitamin K | 2010-02-25 |
20100048705 | METHODS OF TREATING AND PREVENTING NEOVASCULARIZATION WITH OMEGA-3 POLYUNSATURATED FATTY ACIDS - Disclosed are methods for treating or preventing ocular neovascularization in a subject at risk. The method comprises administering to the subject an effective amount of omega-3 polyunsaturated fatty acid to thereby treat or prevent the ocular neovascularization. This method is suitable for treating or preventing retinopathy of prematurity, retina vein occlusion, sickle cell retinopathy, choroidal neovascularization, radiation retinopathy, microangiopathy, retinal hyperoxia, diabetic retinopathy, and age related macular degeneration. Preferably the methods are applied to premature infants, especially those exposed to high levels of oxygen, to treat or prevent ocular neovascularization results from retinopathy of prematurity. Preferably, the omega-3 polyunsaturated fatty acid is administered at high dose, periodically (e.g. from birth) over a prolonged period of time, until the eye is fully vascularized, or to the age of 1 year. Appropriate routes of administration include oral and intravenous administration. Suitable omega-3 polyunsaturated fatty acids include docosahexaenoic acid and eicosapentaenoic acid. These agents can be administered in a pharmaceutically acceptable carrier, e.g. one which contains an anti-oxidant for the omega-3 polyunsaturated fatty acid. | 2010-02-25 |
20100048706 | Ethoxylated and/or Hydrogenated Oil Adduct - A composition of matter comprising an oil adduct synthesized by an oil and an addition material, wherein the oil includes at least one member chosen from an ethoxylated oil, a hydrogenated oil, and an ethoxylated and hydrogenated oil: wherein the average degree of ethoxylation in the ethoxylated (optionally hydrogenated) oil is less than about 10 based on moles of ethylene oxide per mole of oil: wherein the hydrogenated (optionally ethoxylated) oil has an iodine value of less than about 75: wherein the oil is capable of undergoing reaction with the addition material through a hydroxyl group of tile oil; and wherein the addition material includes at least one member chosen from carboxylic acid anhydrides, maleic anhydride, dicarboxylic acids, fumaric acid, maleic acid, succinic acids alpha hydroxy acids, beta hydroxy acids, lactic acid, glycolic acid, lactobionic acid, carnitine, salicylic acid, and (meth)acrylic acid. | 2010-02-25 |
20100048707 | Polymeric Reagents Comprising a Terminal Vinylic Group and Conjugates Formed Therefrom - The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. Methods of making polymeric reagents and conjugates, as well as methods for administering conjugates and compositions, are also provided. | 2010-02-25 |
20100048708 | TAMIBAROTENE CAPSULE PREPARATION - The present invention provides a practical preparation form of Tamibarotene and dosage form thereof, which exhibit high absorptivity by the body with minimized toxicity, and which are safe and stable without any risk of contamination. It is provided a Tamibarotene capsule preparation which encapsulates a composition comprising an oil component as its base and Tamibarotene as an active ingredient dissolved in the base. It is preferred that the oil component be propylene glycol fatty acid esters or polyethylene glycols. It is also preferred that the Tamibarotene capsule preparation comprise 0.1-50 mg/mL of the Tamibarotene based on the oil component. | 2010-02-25 |
20100048709 | Treatment of Prostate Cancer with DDC Inhibitor - Prostate cancer comes in various forms and has proven difficult to treat. Provided herein are various methods and compositions for treating all forms of prostate cancers with dopa decarboxylase (DDC) inhibitors. These dopa decarboxylase inhibitors include carbidopa (α-Methyl-dopahydrazine), MFMD (α-monofluoromethyldopa), NSD-1015 (3-hydroxybenzylhydrazine), Methyldopa (L-α-Methyl-3,4-dihydroxyphenylalanine) or benserazide, and the inhibitors may be used in combination. DDC inhibitors may also be used to inhibit the progression of prostate cancer to androgen-independence and neuroendocrine prostate cancer. | 2010-02-25 |
20100048710 | Methods and Compositions for Modulating Muscle Fat in Livestock - The present invention relates to compositions and methods for modulating the degree of adipose tissue deposited intramuscularly in livestock animals. In particular, the present invention relates to compositions and methods for the use of non-steroidal antiinflammatory drugs to preferentially increase the amount of intramuscular adipose tissue in cattle. | 2010-02-25 |
20100048711 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states - This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans,trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds. | 2010-02-25 |
20100048712 | Acyclic Sulfamide Derivatives - The present invention is related to acyclic sulphamide derivatives of formula (I), wherein R | 2010-02-25 |
20100048713 | COMPOUNDS ACTING ON THE SEROTONIN TRANSPORTER - The invention relates to new chemical compounds acting on the serotonin transporter (SERT), and associated pharmaceutical compositions, methods for use as therapeutic agents, and methods of preparation thereof. In particular the new chemical compounds are useful for the treatment of a variety of central nervous system (CNS) disorders—for example anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, cognitive disorders, sleep disorders, feeding disorders, panic attacks, disorders related to withdrawl from drug abuse, schizophrenia, or the like, or in the treatment of gastrointestinal disorders such as irritable bowel syndrome. | 2010-02-25 |
20100048714 | Methods and Compositions Related to Inhibition of Ceramide Synthesis - Disclosed are compositions and methods related to the ceramide synthesis pathway and various diseases and disorders associated therewith, such as insulin resistance and inflammation. | 2010-02-25 |
20100048715 | INSECTICIDAL COMPOUNDS - A compound of formula (I), wherein A | 2010-02-25 |
20100048716 | CRYSTALLINE FORMS OF ALISKIREN HEMIFUMARATE - This invention relates to crystal forms of aliskiren hemifumarate and various embodiments related thereto, e.g. pharmaceutical preparations, processes for the manufacture of the crystal forms, pharmaceuticals uses and the like. The crystal forms have particularly advantageous properties e.g. they are useful in the manufacture of blood-pressure lowering pharmaceutical preparations and the like. | 2010-02-25 |
20100048717 | CATHEPSIN B INHIBITORS - Compounds of formula (I): are found to be selective inhibitors of cathepsin B, and hence useful in treating a variety of pathological conditions. | 2010-02-25 |
20100048718 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 5.23, 5.03, 4.22 and 4.10 Å, and a process for the preparation thereof. | 2010-02-25 |
20100048719 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 12.31, 8.54, 7.27 and 3.62 Å, and a process for the preparation thereof. | 2010-02-25 |
20100048720 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 14.14, 10.66, 7.80 and 4.02 Å, and a process for the preparation thereof. | 2010-02-25 |
20100048721 | USE OF 2,2,3,3, TETRAMETHYLCYCLOPROPANE CARBOXYLIC ACID DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS - The invention relates to the use of 2,2,3,3 tetramethylcyclopropane carboxylic acid derivative compounds for the preparation of a medicament for treating a psychiatric disorder preferably a bipolar disorder. The invention additionally relates to the use of the compounds for the preparation of an inhibitor of MIP synthase and to a pharmaceutical composition comprising the compounds for treating a psychiatric disorder. A method for treating a psychiatric disorder preferably a bipolar disorder and a method for inhibiting an enzyme having MIP synthase activity is provided. | 2010-02-25 |